Citations (50)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (2)
Oliviero Riggio & Lorenzo Ridola. (2009) Emerging drugs for hepatic encephalopathy. Expert Opinion on Emerging Drugs 14:3, pages 537-549.
Read now
Read now
Lars Bernfort, Karin Sennfält & Olle Reichard. (2006) Cost-effectiveness of peginterferon alfa-2b in combination with ribavirin as initial treatment for chronic hepatitis C in Sweden. Scandinavian Journal of Infectious Diseases 38:6-7, pages 497-505.
Read now
Read now
Articles from other publishers (48)
Aisha Vadhariya, Hua Chen, Omar Serna, Hani Zamil & Susan M. Abughosh. (2020) A retrospective study of drug utilization and hospital readmissions among Medicare patients with hepatic encephalopathy. Medicine 99:16, pages e19603.
Crossref
Crossref
Yanping Cui, Shan Guan, Jie Ding, Yukai He, Qingfang Li, Sikui Wang & Huiling Sun. (2018) Establishment and evaluation of a model for predicting 3-month mortality in Chinese patients with hepatic encephalopathy. Metabolic Brain Disease 34:1, pages 213-221.
Crossref
Crossref
Edward Wolfgang Lee, Sammy Saab, Fady Kaldas, Savannah Fletcher, Ronald W. Busuttil, Francisco Durazo, Justin P. McWilliams, Joseph DiNorcia, Siddharth A. Padia & Stephen T. Kee. (2018) Coil-Assisted Retrograde Transvenous Obliteration (CARTO): An Alternative Treatment Option for Refractory Hepatic Encephalopathy. American Journal of Gastroenterology 113:8, pages 1187-1196.
Crossref
Crossref
D. Katilé, M. Y. Dicko, K. Doumbia Samake, H. Sow Coulibaly, O. Mallé, H. Guindo, S. D. Sanogo Sidibé, A. Maiga, M. C. Tounkara, A. Konaté, M. T. Diarra & M. Y. Maiga. (2017) Encéphalopathie hépatique chez le cirrhotique à BamakoHepatic encephalopathy in cirrhosis in Bamako. Journal Africain d'Hépato-Gastroentérologie 11:2, pages 78-80.
Crossref
Crossref
Timothy F. Platts-MillsNatalie L. RichmondEric M. LeFebvreSowmya A. MangipudiAllison G. HollowellDebbie TraversKevin BieseLaura C. HansonAngelo E. Volandes. (2017) Availability of Advance Care Planning Documentation for Older Emergency Department Patients: A Cross-Sectional Study. Journal of Palliative Medicine 20:1, pages 74-78.
Crossref
Crossref
Duminda Suraweera, Vinay Sundaram & Sammy Saab. (2016) Evaluation and Management of Hepatic Encephalopathy: Current Status and Future Directions. Gut and Liver 10:4, pages 509-519.
Crossref
Crossref
M. Kalafateli, C. K. Triantos, V. Nikolopoulou & A. Burroughs. (2012) Non-variceal Gastrointestinal Bleeding in Patients with Liver Cirrhosis: A Review. Digestive Diseases and Sciences 57:11, pages 2743-2754.
Crossref
Crossref
Amy Matser, Anouk Urbanus, Ronald Geskus, Mirjam Kretzschmar, Maria Xiridou, Marcel Buster, Roel Coutinho & Maria Prins. (2012) The effect of hepatitis C treatment and human immunodeficiency virus (HIV) co-infection on the disease burden of hepatitis C among injecting drug users in Amsterdam. Addiction 107:3, pages 614-623.
Crossref
Crossref
Rebecca Townsend, Phil McEwan, Ray Kim & Yong Yuan. (2011) Structural Frameworks and Key Model Parameters in Cost-Effectiveness Analyses for Current and Future Treatments of Chronic Hepatitis C. Value in Health 14:8, pages 1068-1077.
Crossref
Crossref
Yogesh K Chawla, Ramesh Chillal Kashinath, Ajay Duseja & Radha K Dhiman. (2011) Predicting Mortality Across a Broad Spectrum of Liver Disease—An Assessment of Model for End-Stage Liver Disease (MELD), Child–Turcotte–Pugh (CTP), and Creatinine-Modified CTP Scores. Journal of Clinical and Experimental Hepatology 1:3, pages 161-168.
Crossref
Crossref
Oliviero Riggio. (2010) Hepatic encephalopathy therapy: An overview. World Journal of Gastrointestinal Pharmacology and Therapeutics 1:2, pages 54.
Crossref
Crossref
V.S. Periyakoil. 2010. Sleisenger and Fordtran's Gastrointestinal and Liver Disease. Sleisenger and Fordtran's Gastrointestinal and Liver Disease
2277
2286.e2
.
Gerald Kircheis, Johannes G. Bode, Norbert Hilger, Thomas Kramer, Alfons Schnitzler & Dieter Häussinger. (2009) Diagnostic and prognostic values of critical flicker frequency determination as new diagnostic tool for objective HE evaluation in patients undergoing TIPS implantation. European Journal of Gastroenterology & Hepatology 21:12, pages 1383-1394.
Crossref
Crossref
Uwe Siebert, Gaby Sroczynski, Pamela Aidelsburger, Siegbert Rossol, Jürgen Wasem, Michael P. Manns, John G. McHutchison & John B. Wong. (2009) Clinical Effectiveness and Cost Effectiveness of Tailoring Chronic Hepatitis C Treatment with Peginterferon Alpha-2b Plus Ribavirin to HCV Genotype and Early Viral Response. PharmacoEconomics 27:4, pages 341-354.
Crossref
Crossref
Jiannis Vlachogiannakos, Pantelis Sklavos, Nikos Viazis, Spilios Manolakopoulos, Costas Markoglou, Anastasios Kougioumtzian, Christos Triantos, Jiannis Theodoropoulos, Sotirios Raptis & Dimitrios G Karamanolis. (2008) Long-term prognosis of cirrhotics with an upper gastrointestinal bleeding episode: Does infection play a role?. Journal of Gastroenterology and Hepatology 23:8pt2, pages e438-e444.
Crossref
Crossref
Uday Chand Ghoshal & Ananya Das. (2007) Models for prediction of mortality from cirrhosis with special reference to artificial neural network: a critical review. Hepatology International 2:1, pages 31-38.
Crossref
Crossref
Wei‐Shi Yeh, Edward P. Armstrong, Grant H. Skrepnek & Daniel C. Malone. (2012) Peginterferon alfa‐2a versus Peginterferon alfa‐2b as Initial Treatment of Hepatitis C Virus Infection: A Cost‐Utility Analysis from the Perspective of the Veterans Affairs Health Care System. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 27:6, pages 813-824.
Crossref
Crossref
Z. Benhaddouch, K. Abidi, M. Naoufel, R. Abouqal & A.A. Zeggwagh. (2007) Mortalité et facteurs pronostiques des patients cirrhotiques en encéphalopathie hépatique admis en réanimation. Annales Françaises d'Anesthésie et de Réanimation 26:6, pages 490-495.
Crossref
Crossref
D.N. SAMONAKIS, C.K. TRIANTOS, J. GOULIS & A.K. BURROUGHS. 2007. Surgery of the Liver, Biliary Tract and Pancreas. Surgery of the Liver, Biliary Tract and Pancreas
1563
1578
.
William Sanchez & Jayant A. Talwalkar. (2006) Palliative Care for Patients with End-Stage Liver Disease Ineligible for Liver Transplantation. Gastroenterology Clinics of North America 35:1, pages 201-219.
Crossref
Crossref
Gennaro D'Amico, Guadalupe Garcia-Tsao & Luigi Pagliaro. (2006) Natural history and prognostic indicators of survival in cirrhosis: A systematic review of 118 studies. Journal of Hepatology 44:1, pages 217-231.
Crossref
Crossref
Jayant A. Talwalkar & Patrick S. Kamath. (2005) Influence of Recent Advances in Medical Management on Clinical Outcomes of Cirrhosis. Mayo Clinic Proceedings 80:11, pages 1501-1508.
Crossref
Crossref
Uwe Siebert, Gaby Sroczynski, Jürgen Wasem, Wolfgang Greiner, Ulrike Ravens-Sieberer, Pamela Aidelsburger, Bärbel M. Kurth, Monika Bullinger, J.-Matthias Graf von der Schulenburg, John B. Wong & Siegbert Rossol. (2005) Using competence network collaboration and decision-analytic modeling to assess the cost-effectiveness of interferon α-2b plus ribavirin as initial treatment of chronic hepatitis C in Germany. The European Journal of Health Economics 6:2, pages 112-123.
Crossref
Crossref
María Buti, Ramón San Miguel, Max Brosa, Juan M. Cabasés, Montserrat Medina, Miguel Angel Casado, Leslie Fosbrook & Rafael Esteban. (2005) Estimating the impact of hepatitis C virus therapy on future liver-related morbidity, mortality and costs related to chronic hepatitis C. Journal of Hepatology 42:5, pages 639-645.
Crossref
Crossref
Frédéric Oberti. (2005) Prophylaxie pré-primaire et hypertension portale : vers une prévention universelle de l’hypertension portale ?. Gastroentérologie Clinique et Biologique 29:5, pages 622-625.
Crossref
Crossref
F. Kanwal, G. S. Dulai, B. M. R. Spiegel, H. F. Yee & I. M. Gralnek. (2005) A comparison of liver transplantation outcomes in the pre- vs. post-MELD eras. Alimentary Pharmacology and Therapeutics 21:2, pages 169-177.
Crossref
Crossref
DAWN SEARS & GARY L. DAVIS. 2005. Transplantation of the Liver. Transplantation of the Liver
129
141
.
Edoardo Giannini, Federica Botta, Alessandra Fumagalli, Federica Malfatti, Emanuela Testa, Bruno Chiarbonello, Simone Polegato, Michele Bellotti, Sara Milazzo, Giacomo Borgonovo & Roberto Testa. (2004) Can inclusion of serum creatinine values improve the Child-Turcotte-Pugh score and challenge the prognostic yield of the model for end-stage liver disease score in the short-term prognostic assessment of cirrhotic patients?*. Liver International 24:5, pages 465-470.
Crossref
Crossref
Manuel Romero-Gómez, Lourdes Grande & Inés Camacho. (2004) Prognostic value of altered oral glutamine challenge in patients with minimal hepatic encephalopathy. Hepatology 39:4, pages 939-943.
Crossref
Crossref
Constantinos Chatzicostas, Maria Roussomoustakaki, Georgios Notas, Ioannis G Vlachonikolis, Demetrios Samonakis, John Romanos, Emmanouel Vardas & Elias A Kouroumalis. (2003) A comparison of Child-Pugh, APACHE II and APACHE III scoring systems in predicting hospital mortality of patients with liver cirrhosis. BMC Gastroenterology 3:1.
Crossref
Crossref
G Longheval. (2003) Predictive models of short- and long-term survival in patients with nonbiliary cirrhosis. Liver Transplantation 9:3, pages 260-267.
Crossref
Crossref
Alex Yui Hui, Henry Lik-yuen Chan, Nancy Wai-yee Leung, Lawrence Cheung-tsui Hung, Francis Ka-leung Chan & Joseph Jao-yiu Sung. (2002) Survival and Prognostic Indicators in Patients with Hepatitis B Virus–Related Cirrhosis After Onset of Hepatic Decompensation. Journal of Clinical Gastroenterology 34:5, pages 569-572.
Crossref
Crossref
Bernard T. Brett, Peter C. Hayes & Rajiv Jalan. (2001) Primary prophylaxis of variceal bleeding in cirrhosis. European Journal of Gastroenterology & Hepatology 13:4, pages 349-358.
Crossref
Crossref
A. Albillos Martínez & L. Ruiz del Árbol Olmos. (2001) Tratamiento de la hipertensión portal. Revista Clínica Española 201:9, pages 528-538.
Crossref
Crossref
. (2000) Estimating future hepatitis C morbidity, mortality, and costs in the United States. American Journal of Public Health 90:10, pages 1562-1569.
Crossref
Crossref
María Buti, Miguel A Casado, Leslie Fosbrook, John B Wong & Rafael Esteban. (2000) Cost-effectiveness of combination therapy for naïve patients with chronic hepatitis C. Journal of Hepatology 33:4, pages 651-658.
Crossref
Crossref
Marco Zoli, Carlo Merkel, Donatella Magalotti, Cristina Gueli, Michele Grimaldi, Angelo Gatta & Mauro Bernardi. (2000) Natural History of Cirrhotic Patients With Small Esophageal Varices: A Prospective Study. American Journal of Gastroenterology 95:2, pages 503-508.
Crossref
Crossref
Juan A.del Olmo, Andrés Peña, Miguel A Serra, Abdallah H Wassel, Adolfo Benages & José M Rodrigo. (2000) Predictors of morbidity and mortality after the first episode of upper gastrointestinal bleeding in liver cirrhosis. Journal of Hepatology 32:1, pages 19-24.
Crossref
Crossref
Zobair M. Younossi, Mendel E. Singer, John G. McHutchison & Kenneth M. Shermock. (1999) Cost effectiveness of interferon ?2b combined with ribavirin for the treatment of chronic hepatitis C. Hepatology 30:5, pages 1318-1324.
Crossref
Crossref
Ziv Ben-Ari, Francesco Cardin, Aiden P McCormick, Goya Wannamethee & Andrew K Burroughs. (1999) A predictive model for failure to control bleeding during acute variceal haemorrhage. Journal of Hepatology 31:3, pages 443-450.
Crossref
Crossref
Javier Bustamante, Antoni Rimola, Pere-Joan Ventura, Miquel Navasa, Isabel Cirera, Virginia Reggiardo & Juan Rodés. (1999) Prognostic significance of hepatic encephalopathy in patients with cirrhosis. Journal of Hepatology 30:5, pages 890-895.
Crossref
Crossref
Ottesen, Flyvbjerg, Møller & Bendtsen. (1998) The organ extraction and splanchnic haemodynamic effects of octreotide in cirrhotic patients. Alimentary Pharmacology & Therapeutics 12:7, pages 657-665.
Crossref
Crossref
Karen K. Kormis & George Y. Wu. 1998. Diseases of the Liver and Bile Ducts. Diseases of the Liver and Bile Ducts
385
396
.
Erik Christensen. (1997) Prognostic models in chronic liver disease: validity, usefulness and future role. Journal of Hepatology 26:6, pages 1414-1424.
Crossref
Crossref
Michihiro Sumino, Atsushi Toyonaga & Kyuichi Tanikawa. (1996) Evaluation of patient outcome following sclerotherapy for esophageal varices. Journal of Gastroenterology 31:3, pages 387-393.
Crossref
Crossref
Toshinori Kamiyama, Happei Miyakawa, Kazuo Tajiri, Fumiaki Marumo & Chifumi Sato. (1996) Ischemic Hepatitis in Cirrhosis. Journal of Clinical Gastroenterology 22:2, pages 126-130.
Crossref
Crossref
O Le Moine, M Adler, N Bourgeois, M Delhaye, J Deviere, M Gelin, A Vandermeeren, A Van Gossum, A Vereerstraeten & P Vereerstraeten. (1992) Factors related to early mortality in cirrhotic patients bleeding from varices and treated by urgent sclerotherapy.. Gut 33:10, pages 1381-1385.
Crossref
Crossref
Andrew K. Burroughs & P.Aiden McCormick. (1992) Natural history and prognosis of variceal bleeding. Baillière's Clinical Gastroenterology 6:3, pages 437-450.
Crossref
Crossref